Homology Medicines furnishes Q32 Bio investor presentation for proposed merger; cash runway into mid-2026

Q32 Bio Inc.

Presentation highlights Q32's pipeline: bempikibart (phase 2 for alopecia areata/atopic dermatitis) and ADX-097 (phase 1/2 for complement-mediated diseases).
Combined company expects cash, cash equivalents and short-term investments to fund operations into mid-2026.
Merger expected to close in Q1 2024, subject to Homology stockholder approval and other customary conditions.
CVRs may provide contingent payments to Q32 stockholders based on future milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.